SCHEMBL22801693

SCHEMBL22801693

NC(=O)c1cccc(-c2n[nH]c3ccc(C(F)(F)F)cc23)c1

nearest known ligand 0.76

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 10/20 0.76
MAPK1 P28482 5/20 0.62
MAPK6 Q16659 5/20 0.62
MAPKAPK3 Q16644 4/20 0.62
TTK P33981 2/20 0.60
MAPK8 P45983 2/20 0.60
MAPKAPK2 P49137 2/20 0.57
PIM1 P11309 3/20 0.56
MAP3K5 Q99683 2/20 0.53
MAPK10 P53779 1/20 0.51
MAPK14 Q16539 1/20 0.51
MAPKAPK5 Q8IW41 2/20 0.50
LRRK2 Q5S007 1/20 0.46
PDPK1 O15530 1/20 0.46
DHODH Q02127 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22819421 0.86 MAP2K4 (1.00) MAP2K4MAPK1MAPK6MAPKAPK3TTK
SCHEMBL14514462 0.82 PDGFRB (0.63) MAP2K4MAP3K5LRRK2
SCHEMBL22819366 0.81 MAP2K4 (1.00) MAP2K4MAPK1MAPK6MAPKAPK3TTK
SCHEMBL2860093 0.79 MAP2K4 (0.71) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL5377653 0.79 MAP2K4 (0.73) MAP2K4MAPK1MAPK6MAPKAPK3TTK
SCHEMBL5801740 0.79 MAP2K4 (0.65) MAP2K4MAPK1MAPK6MAPKAPK3TTK
SCHEMBL5374141 0.78 MAP3K5 (0.57) MAP2K4MAPK1MAPK6MAPKAPK3TTK
SCHEMBL22801797 0.77 MAP2K4 (1.00) MAP2K4MAPK1MAPK6MAPKAPK3MAPK8
SCHEMBL5374481 0.77 MAP2K4 (0.67) MAP2K4MAPK1MAPK6MAPKAPK3TTK
SCHEMBL5382810 0.76 MAP2K4 (0.65) MAP2K4MAPK1MAPK6MAPKAPK3TTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11370770-B2 3-arylindazoles as selective MEK4 inhibitors NORTHWESTERN UNIVERSITY (US) 2022-06-28 US disclosed
US-11370770-B2 3-arylindazoles as selective MEK4 inhibitors NORTHWESTERN UNIVERSITY (US) 2022-06-28 US disclosed
US-20200399241-A1 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS NORTHWESTERN UNIVERSITY (US) 2020-12-24 US disclosed
US-20200399241-A1 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS NORTHWESTERN UNIVERSITY (US) 2020-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399241-A1 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS MAP4K3, MAPK4, MAP3K4 MAP2K4 39/4885MAPK1 32/4885MAPK6 42/4885
US-11370770-B2 3-arylindazoles as selective MEK4 inhibitors MAP4K3, MAPK4, MAP3K4 MAP2K4 39/4885MAPK1 32/4885MAPK6 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.